Neoadjuvant Pyrotinib Combined With Trastuzumab, Carboplatin and Paclitaxel for ER+/HER2+ Breast Cancer
Breast Cancer
Enrolment: 62 · Results not recorded
Loading the evidence…
Biologic · Receptor protein-tyrosine kinase erbB-2 (HER2) inhibitor (INHIBITOR)
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Breast Cancer
Enrolment: 62 · Results not recorded
Leptomeningeal Metastasis
Enrolment: 26 · Results not recorded
Gastric Cancer
Enrolment: 50 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Common peroneal nerve transection with immediate surgical repair
Trastuzumab had no impact on the numbers of motor or sensory neurons regenerating their axons and did not alter ErbB2 or phospho-ErbB2 expression levels, but significantly increased the number of regenerated axons in the distal repaired nerve at 4 weeks, indicating more axons emitted per regenerati…
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
Model: Common peroneal nerve transection with immediate repair or repair after 4 months of chronic denervation
Trastuzumab increased the rate of motor and sensory neuron regeneration, Schwann cell proliferation in the distal stump, and the number of myelinated axons regenerating after both immediate and delayed repair.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.